DGAP-News

Press Release 4SC AG: Dr Susanne Danhauser-Riedl joins 4SC as Chief Medical Officer to strengthen management and clinical development team - Seite 2

Technische Universität München (TUM), Germany and has the European Diploma
for Pharmaceutical Medicine (ECPM, University of Basel, Switzerland). She
is a member of the German Society for Haematology and Oncology (DGHO), the
German Society for Pharmaceutical Medicine (DGPharMed) and the American
Society of Clinical Oncology (ASCO).

Enno Spillner, Chief Executive Officer and Chairman of the Management Board
of 4SC AG commented: "We are very pleased to be able to bring Dr
Danhauser-Riedl on board as our Chief Medical Officer. With her extensive
and long-standing experience in research, clinical practice and the
pharmaceutical industry, she provides broad-based support for our plans to
press on with the further clinical development of our promising oncology
pipeline and thus establish a strong portfolio of high-value cancer
therapies."

Dr Susanne Danhauser-Riedl added: "I look forward to my exciting new role
at 4SC. I believe 4SC possesses an extremely attractive oncology portfolio
- not least because epigenetics is a very interesting research field within
medicine. Together with the R&D team of 4SC, we want to advance the drug
candidates swiftly, first and foremost to provide patients with a
significant clinical benefit."

End of press release

About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various cancer and autoimmune indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's pipeline comprises promising products that are in
various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount
of 66 employees (57 FTEs) at 31 December 2014. 4SC AG has been listed on
the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the